Phase 3 trial in 501 BCG-naive patients with non-muscle-invasive bladder cancer: BCG plus mitomycin was not superior to BCG alone for disease-free survival (2-year 75% vs 71%; HR 0.87, p=0.3), but used fewer BCG doses. Grade 3-5 adverse events: 43 vs 37.
RCTn = 501
Hayne et al. Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)